News

Atezolizumab Added to FOLFOXIRI and Bevacizumab Safe, Effective for Metastatic Colorectal Cancer

06/14/2022

Findings from the phase 2 AtezoTRIBE trial show that the addition of atezolizumab to FOLFOXIRI and bevacizumab is safe and effective for patients with previously untreated metastatic colorectal cancer.

Findings from the phase 2...

06/14/2022

Oncology

News

Shorter Duration of Adjuvant Therapy Does Not Compromise Efficacy in Colon Cancer: ACHIEVE Trial

05/19/2022

Amber Denham ;

Study findings show that shortening adjuvant FOLFOX or CAPOX therapy from 6 to 3 months did not compromise efficacy among Asian patients with curatively resected colon cancer.

Study findings show that...

05/19/2022

Oncology

News

Primary Tumor Resection Before Systemic Treatment Increases Mortality Among Patients With Metastatic Colorectal Cancer

05/03/2022

Janelle Bradley ;

Findings from the phase 3 CAIRO4 trial suggest patients with metastatic colorectal cancer who received primary tumor resection followed by systemic treatment had higher 60-day mortality than those randomized to systemic treatment alone.

Findings from the phase 3 CAIRO4...

05/03/2022

Oncology

News

Pembrolizumab Does Not Improve OS Over Chemotherapy in Patients With Colorectal Cancer: KEYNOTE-177

05/02/2022

John Otrompke , BA, JD;

Superior OS for pembrolizumab over chemotherapy was not established among patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in the phase 3 KEYNOTE-177 study.

Superior OS for pembrolizumab...

05/02/2022

Oncology

News

Debates and Updates of VEGF Superiority in RAS Wild-Type CRC

03/26/2022

Cathy Eng, MD, FACP, FASCO, argued for VEGF therapy versus anti-EGFR inhibition in a debate with Dr Kasi at the 2022 GDU GI conference in New York, NY.

Cathy Eng, MD, FACP, FASCO,...

03/26/2022

Oncology

News

First-Line Treatment in Left-Sided, RAS/BRAF Wild-Type Metastatic Colorectal Cancer: EGFR Inhibitors vs VEGF Inhibitors

03/26/2022

Alex Stoia ;

Pashtoon M. Kasi, MD, MS, argued for EGFR inhibitors as a superior first-line treatment vs VEGF in a debate with Cathy Eng, MD, FACP, FASCO, at the 2022 Great Debates and Updates in GI Malignancies meeting.

Pashtoon M. Kasi, MD, MS, argued...

03/26/2022

Oncology

News

FDA Approves Cetuximab-Based Combo for Colorectal Cancer Subset

10/19/2021

The FDA has approved cetuximab and encorafenib as a combination treatment for patients with a BRAF V600E mutation in metastatic colorectal cancer.

The FDA has approved cetuximab...

10/19/2021

Oncology

News

Pembrolizumab Plus CRT Combo Found Unbeneficial in LARC

09/01/2021

Data from the NRG-GI002 trial indicate that neoadjuvant pembrolizumab plus CRT after FOLFOX treatment provides no benefit as a combination therapy for patients with LARC.

Data from the NRG-GI002 trial...

09/01/2021

Oncology

Conference Insider

Neoadjuvant Chemoradiotherapy Enhances Tumor Response in LARC

06/29/2021

According to data presented at the virtual ESMO World Congress on GI Cancer, neoadjuvant chemoradiotherapy enhances tumor response in patients with LARC.

According to data presented at ...

06/29/2021

Oncology

Conference Insider

Real-World Study Shows Trifluridine/Tipiracil Plus Bevacizumab Effective for mCRC

06/29/2021

Study findings presented at the virtual ESMO World Congress on GI Cancer suggest that trifluridine/tipiracil plus bevacizumab is effective for patients with refractory metastatic colorectal cancer.

Study findings presented at the...

06/29/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology